Bio Business
The CAR T-Cell Race
The CAR T-Cell Race
Vicki Brower | Apr 1, 2015
Tumor-targeting T-cell therapies are generating remarkable remissions in hard-to-beat cancers—and attracting millions of dollars of investment along the way.
Lazarus Drugs
Lazarus Drugs
Kate Yandell | Feb 1, 2015
While some drugs sail through development, others suffer setbacks, including FDA rejections, before reaching the market.
 
Cannabis Biotech
Cannabis Biotech
Daniel Cossins | Dec 1, 2014
As medical marijuana businesses set up shop across the U.S., a handful of companies are taking the pharmaceutical route, guiding cannabis-derived drugs through clinical trials.
Eyes on the Prize
Eyes on the Prize
Jeffrey M. Perkel | Oct 1, 2014
A handful of stem cell therapeutics for vision disorders are showing promise in early-stage trials, and still more are in development. But there’s a long road to travel before patients see real benefit.
 
That Loving Feeling
That Loving Feeling
Megan Scudellari | Jul 1, 2014
There are no FDA-approved drugs to treat low sexual desire in women, but not for lack of trying.
Sharing the Wealth
Sharing the Wealth
Jef Akst | May 1, 2014
From research results to electronic health records, biomedical data are becoming increasingly accessible. How can scientists best capitalize on the information deluge?
Incubator Boom
Incubator Boom
Kerry Grens | Mar 1, 2014
From San Francisco to St. Louis, biotech incubators are proliferating across North America. Can they deliver on their promise of fueling the economy?
 
Outwitting the Perfect Pathogen
Outwitting the Perfect Pathogen
Megan Scudellari | Jan 1, 2014
Tuberculosis is exquisitely adapted to the human body. Researchers need a new game plan for beating it.
Penetrating the Brain
Penetrating the Brain
Megan Scudellari | Nov 1, 2013
Researchers use molecular keys, chisels, and crowbars to open the last great biochemical barricade in the body—the blood-brain barrier.
Remaking a Classic
Remaking a Classic
Megan Scudellari | Sep 1, 2013
Companies are bursting at the seams with tools to engineer pharma’s next magic bullet: the new and improved antibody.